SecBot SecBot
PRESS-RELEASE ·Filed Mar 27, 2026

PVLA

Palvella Therapeutics Inc.
MIXED
Impact 6/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ◆ Mixed

Traders should monitor upcoming clinical milestones, particularly the initiation of the Phase 2 trial for QTORIN™ pitavastatin and any regulatory feedback. The strong Phase 3 data for QTORIN™ rapamycin supports valuation, but lack of revenue-generating products and near-term commercial catalysts limits immediate upside.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$112.37
T+0 close · Mar 27, 2026 · via day close
Latest settled
+13.40%
T+60 · $127.43
Vs SPY
−2.66%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 27 $112.37entry
  2. T+1 · 8mo ago −1.52%α −1.16% · $110.66
  3. T+5 · 8mo ago +6.67%α +2.80% · $119.86
  4. T+20 · 7mo ago +14.48%α +1.74% · $128.64
  5. T+60 · 5mo ago +13.40%α −2.66% · $127.43
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Palvella Therapeutics presented two posters at the 2026 American Academy of Dermatology meeting: one highlighting the technical advantages and clinical success of its QTORIN™ rapamycin gel in treating rare skin diseases, and another detailing the significant patient burden of porokeratosis, a rare genetic skin condition with no FDA-approved therapies. The company is advancing QTORIN™ rapamycin through Phase 3 trials and plans to initiate a Phase 2 trial for QTORIN™ pitavastatin in porokeratosis in the second half of 2026.

Key Facts

  • QTORIN™ rapamycin met primary and all secondary endpoints in the Phase 3 SELVA study for microcystic lymphatic malformations (p<0.001).
  • Systemic rapamycin levels remained below 2 ng/mL, indicating favorable safety and localized delivery.
  • Poster #76929 highlights substantial physical, psychosocial, and cancer-related burdens in porokeratosis patients based on 10 qualitative interviews.
  • No FDA-approved therapies currently exist for porokeratosis, affecting over 50,000 diagnosed U.S. patients.
  • Phase 2 trial for QTORIN™ pitavastatin in disseminated superficial actinic porokeratosis (DSAP) is expected to begin in H2 2026.

Financial Impact

No direct financial impact disclosed; development-stage updates may influence investor sentiment and valuation.

pipeline progressR&D trajectorymarket opportunity

Risk Factors

  • QTORIN™ candidates remain investigational with no guarantee of regulatory approval.
  • Clinical development timelines may be delayed despite stated expectations.
  • Competition from off-label or compounded rapamycin formulations, though less stable, could limit market adoption.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3263839

Track record

36 reports on PVLA

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 8 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
  2. Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
  3. Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 Now $144.60 −7.81% settles Dec 4
  4. Nov 5, 202611d ago Press Release Neutral 6/10 No price data
  5. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
  6. Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  7. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  8. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  9. Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
  10. Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens in 6h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 27, 2026